Full-Time
Microbiology Laboratory Technician
IDEXX
5,001-10,000 employees
Veterinary diagnostics, lab services, software
Compensation Overview
$21 - $25/hr
No H1B Sponsorship
Columbia, MO, USA
In Person
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to IDEXX
See people who can refer or advise you
- A 4-year degree in a science-related field is required.
- Recent college graduates with a relevant degree and college coursework may be considered for an entry-level role.
- Ability to apply analytical thinking while operating laboratory instruments and interpreting data.
- Ability to organize work and multitask.
- Ability to pay close attention to detail in a fast-paced environment.
- Applicants must be authorized to work for any employer in the United States.
- The role involves potential exposure to biohazards, agents known to cause zoonotic diseases, and hazardous chemicals.
- Reliable and dependable attendance is an essential function of the position.
- Perform microbiology culture setup.
- Interpret bacterial and fungal colony morphologies.
- Identify bacteria and fungi using MALDI-TOF MS and/or biochemical testing.
- Perform antibiotic sensitivity testing.
- Make microbiology culture media.
- Perform other duties as assigned.
- A 4-year degree in a science-related field, ideally Microbiology or Biology with strong microbiology coursework.
- At least 1 year of experience performing microbiology setup and interpretive testing.
IDEXX Laboratories provides veterinary diagnostics, laboratory services, and practice management software for companion animals, livestock, and related markets. Its offerings include in-clinic diagnostic instruments and tests, centralized reference labs, and software subscriptions that streamline testing, data management, and workflows. The company differentiates itself with a vertically integrated, end-to-end ecosystem that combines clinical diagnostics, laboratory services, and software. Its goal is to improve animal health outcomes and veterinary practice efficiency through accurate testing and data-driven decision making.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Westbrook, Maine
Founded
1983
Get referred to IDEXX
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 10% to $1.22 billion, with guidance raised again.
- Cancer Dx launched in the UK on April 1, 2026, broadening oncology screening.
- Catalyst proBNP and SDMA expansions deepen high-margin testing across cats and dogs.
What critics are saying
- Twenty-two pet owners sued IDEXX in California in 2025 over anticompetitive contracts.
- FTC scrutiny already targeted IDEXX exclusivity, undermining distribution leverage and inviting new challenges.
- Zoetis and Antech keep expanding diagnostics, pressuring IDEXX pricing and share through 2026.
What makes IDEXX unique
- IDEXX installed 80,000 Catalyst analyzers globally, locking clinics into recurring consumables.
- IDEXX launched inVue Dx, reaching 9,000 instruments and accelerating point-of-care cytology adoption.
- IDEXX combines diagnostics, reference labs, and practice software into one sticky veterinary workflow.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Mental Health Support
Pet Insurance
Employee Stock Purchase Plan
Volunteer Paid Days Off
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 7%2 year growth
↑ 7%IDEXX Laboratories has launched the Catalyst proBNP Test, the first dual-species, in-clinic test for NT-proBNP biomarker to evaluate heart disease in cats and dogs. The test runs on IDEXX's Catalyst platform, which has nearly 80,000 analyzers installed globally. The test delivers results during patient visits, reducing reliance on referrals and expanding access to cardiac assessment where specialist services are limited. It supports screening, diagnosis, and monitoring of heart disease, which affects approximately one in six cats and one in 10 dogs. IDEXX estimates the global cardiac testing opportunity at approximately $4 billion. The test will be available in North America from October 2026, with international rollout to follow.
IDEXX Q2 earnings jump 18%, beating expectations. August 4, 2026 IDEXX Laboratories Inc. (Nasdaq: IDEXX) posted second-quarter results that exceeded Wall Street expectations and again raised its full-year financial outlook. The Westbrook-based maker of veterinary diagnostics and software posted diluted earnings per share of $4.27, representing an increase of 18% as reported and 15% on a comparable basis from a year ago. The figure exceeds that $3.95 per share consensus estimate of analysts polled by Zacks Investment Research. It also includes 14 cents a share in tax benefits from share-based compensation and a boost of 6 cents a share from year-over-year currency changes. In each of the past four quarters, the company has surpassed consensus earnings estimates. Q2 revenue was $1.22 billion, an increase of 10% as reported and 9% organic, driven by growth in the company's Companion Animal Group division. The figure is 1.28% above the Zacks consensus estimate. Mike Erickson, who recently took the helm as IDEXX's president and CEO, said the results reflect continued innovation across various diagnostic platforms. "This is the kind of durable, compounding growth we're building for the long term, helping veterinarians see more and do more for their patients while creating lasting value for our shareholders," he added. As of Monday's close on Wall Street, IDEXX shares have a market value of around $44.8 billion. That's 17% lower than a year ago. Updated outlook. In its updated outlook for the full year, IDEXX is projecting earnings per share to be in the range of $14.69 to $14.94. That's 14 cents higher at the midpoint level than previously. IDEXX also expects full-year revenue guidance to be in the range of $4.7 billion to $4.75 billion, or reported growth of 9.1% to 10.3%. That represents an increase of $5 million at midpoint, despite a stronger U.S. dollar resulting in a $15 million net reduction to projected revenues. IDEXX increased its full-year reported operating margin outlook to 32.3% to 32.5%, bringing the projected full-year operating profit margin expansion to 70 to 90 basis points as reported and on a comparable basis. IDEXX said the updated outlook benefits from strong second-quarter operating performance along with advancing strategic investment priorities. The company also projects a higher full-year reported operating margin, citing strong second-quarter operating performance and a focus on strategic investments. - Digital Partners -
IDEXX Laboratories reported second quarter 2026 revenue of $1,217 million, up 10% as reported and 9% organically. Companion Animal Group Diagnostics recurring revenue grew 11% as reported and 10% organically, driven by volume and expanding diagnostics utilization. The company's IDEXX inVue Dx installed base exceeded 9,000 instruments, with over 1,600 placements during the quarter. Earnings per share reached $4.27, up 18% as reported and 15% on a comparable basis. Operating margin increased 140 basis points as reported. IDEXX narrowed its 2026 revenue guidance to $4,700-$4,745 million and raised its EPS outlook to $14.69-$14.94, representing a $0.14 increase at midpoint. The company expects organic revenue growth of 8.5%-9.7% for the full year.
ElleVet Sciences expands leadership team with two key additions. * Posted On - * Published - Jul 22, 2026 ElleVet Sciences expands its leadership team, appointing Robyn Cash and Ryan Dean to lead Human Resources and Finance SOUTH PORTLAND, MAINE (July 22, 2026) - ElleVet Sciences, the science-backed leader in CBD + CBDA products for pets, is proud to announce two key additions to the organization's leadership team with the promotion of Robyn Cash to Director, Human Resources and the hiring of Ryan Dean as Senior Director, Finance. "ElleVet continues to invest significantly in clinical research, analytical capabilities, and science-driven product development to provide groundbreaking, highly effective supplements to veterinarians and pet parents. Robyn and Ryan are valuable additions to the leadership team - attracting and retaining top talent and optimizing strong financial competencies is critical for us as we continue to grow and scale," said Christian Kjaer, Executive Chair and cofounder of ElleVet Sciences. Robyn Cash joined ElleVet in 2023 as Senior Recruiter, where she helped develop ElleVet's growing team. "I am proud to be part of ElleVet Sciences, a company driven by science, backed by a successful history, and positioned for an exciting future," said Cash, who now leads the Human Resources function. "This promotion provides an opportunity for me to contribute even more to ElleVet's strategic direction while continuing to support the growth and development of the exceptional talent we have across the organization." Ryan Dean, formerly of IDEXX, joined ElleVet in July as Senior Director of Finance. Dean shared, "I am looking forward to leading the finance team at ElleVet and helping shape the next chapter of the organization by building on the strong foundation in place. I am grateful to work for a science-focused, mission-driven organization and am energized by the fact that our work helps pets live better lives." Over the years, ElleVet Sciences has invested in more than 40 clinical studies and R&D initiatives and published more than 23 peer-reviewed studies demonstrating the safety and efficacy of its products, reflecting the company's commitment to developing the best possible products for pets. As the company continues to grow, ElleVet is strengthening its organization to accelerate innovation, advance its mission, and meet increasing customer demand. About ElleVet Sciences: ElleVet Sciences is a leading science-driven animal health company headquartered in South Portland, Maine. As the first organization to conduct successful clinical trials on the safety and efficacy of CBD + CBDA for pets, ElleVet continues to lead the field through research and innovation in collaboration with top veterinary professionals and institutions. The company has pioneered and patented safe, effective products for dogs, cats, and horses, offering support for mobility, stress, skin health, and brain function. Carried by thousands of veterinary clinics across the US, ElleVet is committed to improving the lives of companion animals, with both heart and science at the core of its mission.
IDEXX Laboratories has announced two significant upgrades to its diagnostic services at no additional cost to customers. Beginning late June, the company will expand its Fecal Dx antigen testing platform across the US and Canada to include detection of taeniid tapeworm species, including Taenia and Echinococcus. The enhanced testing can detect up to twice as many infections earlier than traditional methods. Additionally, IDEXX will integrate its SDMA renal biomarker into Catalyst CLIPs from June, making comprehensive kidney function evaluation standard in point-of-care chemistry profiles. Since launching the SDMA Test in 2015, the company has performed approximately 119 million tests globally. The Maine-based veterinary diagnostics firm specialises in diagnostic instruments, testing kits and reference laboratory services for veterinarians.